Do You Have Insulin Resistance?
Most people with IR don’t know it — until it shows up as something else. Here’s what the science says, and a validated tool to check your numbers.
Check your HOMA-IR scoreUnderstanding insulin resistance
Your cells have stopped listening to insulin
Insulin is the body’s master regulator of blood glucose — a peptide hormone secreted by pancreatic beta cells that signals peripheral tissues to take up glucose from the bloodstream. Under normal physiological conditions, this feedback loop is seamless: glucose rises after a meal, insulin is released, cells respond, glucose returns to baseline.
Insulin resistance disrupts this system. Target tissues — primarily skeletal muscle, the liver, and adipose tissue — become less responsive to insulin’s signal. The pancreas compensates by producing progressively more insulin to achieve the same metabolic effect. For years, blood glucose may remain relatively normal while insulin levels quietly climb. This is hyperinsulinaemia: metabolically costly, largely invisible on a standard glucose panel, and an early warning sign that the system is under strain.
Insulin is the key. Your cell is the door. In a healthy system, one insulin key fits the cell’s receptor lock — the door opens, glucose flows in for energy, blood sugar returns to baseline. One key. One lock. Clean and efficient.
The lock becomes stiff. The key still works, but your pancreas must produce 2–3× more insulin to open it. Fasting glucose still looks normal on a standard blood test — but fasting insulin is rising. This is exactly what HOMA-IR is designed to catch.
The lock is jammed. Even flooding the system with insulin cannot open the cell door. Glucose accumulates in the bloodstream — now visible on a fasting glucose test. When beta cells can no longer compensate, this becomes type 2 diabetes.
Your personal assessment
Calculate your HOMA-IR
Enter your fasting blood values — from a morning blood draw, minimum 8 hours fasted. Values from random or post-meal tests will not yield accurate results.
HOMA-IR Calculator
Based on Matthews et al., Diabetologia 1985 · Enter fasting values only
| HOMA-IR | Category | Clinical significance |
|---|---|---|
| < 1.0 | Optimal | Normal insulin sensitivity |
| 1.0 – 1.9 | Borderline | Early metabolic strain; warrants attention |
| 2.0 – 2.9 | Insulin Resistance | Clinically significant IR by most definitions |
| ≥ 3.0 | Significant IR | Substantial metabolic burden; clinical review recommended |
—
—
The physiological cascade
How insulin resistance develops
Insulin resistance is not a single-step failure — it is a progressive dysregulation across multiple tissues. Step through the stages below.
Excess caloric load
Chronic energy surplus leads to ectopic lipid accumulation in liver and skeletal muscle. This disrupts insulin receptor signalling — IRS-1 phosphorylation and downstream PI3K/Akt pathway activation are impaired, reducing GLUT4 translocation to cell membranes and cutting glucose uptake at the cellular level.
Adipose inflammation
Dysfunctional adipose tissue releases pro-inflammatory adipokines, cytokines (TNF-α, IL-6), chemokines, excess free fatty acids, and toxic lipid metabolites. These circulate systemically and impair insulin signalling in skeletal muscle, liver, and other peripheral tissues — amplifying resistance beyond the initial site of dysfunction.
Hepatic glucose excess
Insulin-resistant hepatocytes fail to suppress gluconeogenesis. Normally, insulin would inhibit hepatic glucose output; here the liver continues producing and releasing glucose despite elevated circulating insulin levels — a selective hepatic insulin resistance that drives fasting hyperglycaemia even while peripheral glucose uptake remains partly intact.
Pancreatic compensation
Beta cells upregulate insulin secretion to maintain normal fasting glucose. Blood glucose appears normal on a standard panel — but fasting insulin is elevated. This is the hallmark compensatory hyperinsulinaemia that HOMA-IR is specifically calibrated to detect and quantify. Left unaddressed, this sustained demand accelerates the next stage.
Beta cell fatigue
Sustained hypersecretion eventually exceeds beta cell functional capacity. Cells undergo oxidative stress, endoplasmic reticulum stress, and eventually apoptosis. The compensatory mechanism fails: insulin secretion falls while insulin resistance remains. Fasting glucose begins to rise — transitioning toward impaired fasting glucose, pre-diabetes, and then type 2 diabetes.
Systemic consequences
Dyslipidaemia (elevated TGs, low HDL), hypertension, non-alcoholic fatty liver disease, PCOS, and cardiovascular disease each have insulin resistance as a core pathophysiological driver. IR also fosters a tumour-favorable microenvironment and is associated with elevated cancer risk — underscoring why early detection and intervention matters profoundly.
Downstream consequences
Conditions that share insulin resistance as a driver
Insulin resistance rarely operates in isolation — it is the metabolic underpinning for a range of chronic conditions. Recognising and addressing it early can meaningfully shift trajectory across each of these.
Type 2 Diabetes
Tap to reveal
Type 2 Diabetes
IR precedes T2DM by up to 15 years. Beta-cell compensation eventually fails, leading to frank hyperglycaemia. Addressing IR early is addressing diabetes risk before it manifests.
Cardiovascular Disease
Tap to reveal
Cardiovascular Disease
Endothelial dysfunction, atherogenic dyslipidaemia (elevated TGs, low HDL), and hypertension are each mechanistically linked to IR. Risk is elevated well before glucose abnormalities appear.
Non-Alcoholic Fatty Liver
Tap to reveal
Non-Alcoholic Fatty Liver
Hepatic IR promotes ectopic fat deposition and impaired lipid metabolism, driving steatosis and steatohepatitis. NAFLD and IR exist in a bidirectional, self-worsening relationship.
PCOS
Tap to reveal
PCOS
Up to 80% of women with PCOS have IR. Hyperinsulinaemia stimulates excess ovarian androgen production and disrupts LH pulsatility, impairing ovulatory function and hormonal balance.
Metabolic Syndrome
Tap to reveal
Metabolic Syndrome
Central obesity, hypertriglyceridaemia, low HDL, hypertension, and dysglycaemia — IR is the common biological thread linking all five components in a self-amplifying cycle.
Energy & Hormonal Dysregulation
Tap to reveal
Energy & Hormonal Dysregulation
Chronic hyperinsulinaemia suppresses fat oxidation, dysregulates leptin and ghrelin signalling, and drives persistent fatigue, weight resistance, and carbohydrate cravings.
Self-assessment
Do you recognise any of these?
Tick any symptoms you experience. This is not a diagnostic tool — but it may be a useful prompt to look more closely at your metabolic health.
Symptom check-in
Select the symptoms you recognise above.
Scientific basis
References
All content on this page is grounded in peer-reviewed research.
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. [IF ~8.4]
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495. [IF ~16.2]
- Deng X, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy. 2022;7:216. [IF ~39.3]
- Armandi A, et al. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites. 2021;11(3):155.
- Xiong X, et al. The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in Endocrinology. 2023;14:1149239. [IF ~5.2]
- Agrawal A, Dave A, Jaiswal A. Type 2 diabetes mellitus in patients with polycystic ovary syndrome. Cureus. 2023;15(10):e46859.
- DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology. 1979;237(3):E214–E223.
- Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191–2192.
- Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab. 2009;297(3):E578–E591.
Your numbers are a starting point, not a verdict.
If your HOMA-IR is elevated, targeted nutrition and lifestyle intervention can meaningfully shift it. Book a free discovery call to explore what this means for you.
Book a Free Discovery Call